Company / Current Liabilities
Barinthus Biotherapeutics plc. Current Liabilities History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$10.0M
FY2025
5-year range
$10.0M / $15.7M
FY2021-FY2025
Trend
-36.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $13M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2025 with a 3-year CAGR of -6.5%.
Improved from $13M to $10M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -6.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -6.5%, indicating a declining trend.
- In FY2025, current liabilities decreased 36.0% year-over-year.
- Peak current liabilities was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.0M | -36.0% |
| FY2024 | $15.7M | +24.3% |
| FY2023 | $12.6M | +2.9% |
| FY2022 | $12.2M | +9.7% |
| FY2021 | $11.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026